T
Tomoko Inoue
Researcher at Mie University
Publications - 14
Citations - 296
Tomoko Inoue is an academic researcher from Mie University. The author has contributed to research in topics: Apoptosis & Survivin. The author has an hindex of 9, co-authored 14 publications receiving 290 citations.
Papers
More filters
Journal ArticleDOI
Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death
Yumi Yamaguchi,Katsuya Shiraki,Hiroyuki Fuke,Tomoko Inoue,Kazumi Miyashita,Yutaka Yamanaka,Yukiko Saitou,Kazushi Sugimoto,Takeshi Nakano +8 more
TL;DR: Downregulation of the XIAP or survivin enhances cell death by TRAIL and increases sensitivity against some chemotherapeutic agents in HCC cells, and may be a potential target to increase therapeutic sensitivity.
Journal ArticleDOI
Risk factors for the recurrence of hepatocellular carcinoma after radiofrequency ablation of hepatocellular carcinoma in patients with hepatitis C.
Yutaka Yamanaka,Katsuya Shiraki,Kazumi Miyashita,Tomoko Inoue,Tomoyuki Kawakita,Yumi Yamaguchi,Yukiko Saitou,Norihiko Yamamoto,Takeshi Nakano,Atsuhiro Nakatsuka,Koichiro Yamakado,Kan Takeda +11 more
TL;DR: Patients who have multiple HCC nodules, low serum platelets and low serum albumin accompanied by HCV infection, should be carefully followed because of the high incidence of new HCC lesions in the remnant liver, even if coagulation RFA is complete.
Journal ArticleDOI
COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis
Yutaka Yamanaka,Katsuya Shiraki,Tomoko Inoue,Kazumi Miyashita,Hiroyuki Fuke,Yumi Yamaguchi,Norihiko Yamamoto,Keiichi Ito,Kazushi Sugimoto,Takeshi Nakano +9 more
TL;DR: It is demonstrated that COX-2 inhibitors can induce apoptosis and augment TRAIL sensitivity by up-regulation of TRAIL receptors and down- regulation of both survivin and AKT signaling.
Journal ArticleDOI
Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway.
Tomoko Inoue,Katsuya Shiraki,Hiroyuki Fuke,Yutaka Yamanaka,Kazumi Miyashita,Yumi Yamaguchi,Norihiko Yamamoto,Keiichi Ito,Kazushi Sugimoto,Takeshi Nakano +9 more
TL;DR: Combining proteasome inhibitors with a TRAIL agonist may provide a new therapeutic strategy for HCC, as both inhibitors induced apoptosis and augmented TRAIL sensitivity via both the IAP family and AKT pathways.
Journal ArticleDOI
Involvement of tumor necrosis factor–related apoptosis-inducing ligand and tumor necrosis factor–related apoptosis-inducing ligand receptors in viral hepatic diseases
Yukiko Saitou,Katsuya Shiraki,Hiroyuki Fuke,Tomoko Inoue,Kazumi Miyashita,Yutaka Yamanaka,Yumi Yamaguchi,Norihik Yamamoto,Keiichi Ito,Kazushi Sugimoto,Takeshi Nakano +10 more
TL;DR: Flow cytometry analysis revealed that both TRAIL-R2 and TRAIL were up-regulated on the cell surface of HepG2 cells with AdCMVLacZ infection, indicating that TRAIL/TRAil-R apoptotic pathways play important roles in the hepatic cell death during viral infection.